Stock Track | Innovent Bio Soars 5.06% Intraday on Strong Q1 Revenue Growth Exceeding 50%

Stock Track04-30

Innovent Biologics' stock soared 5.06% during intraday trading on Thursday, following the release of its first-quarter 2026 financial results.

The company reported total product revenue exceeding RMB3.8 billion for Q1 2026, representing year-over-year growth of over 50%. This robust performance demonstrates the successful execution of the company's "dual-engine" growth strategy, combining domestic business expansion with accelerating global innovation pipeline development.

Revenue growth was driven by rapid sales expansion of five tyrosine kinase inhibitors following their recent inclusion in China's National Reimbursement Drug List, along with strong performance from core products including Xelmei® (Mazdutide Injection), Xinbile® (Tolecimab Injection), and Xinbimin® (Tituyou Monoclonal Antibody N01 Injection). The company is also advancing three high-value potential molecules—IBI363, IBI343, and IBI324—into or toward global multi-center Phase III clinical studies, bolstering its long-term growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140158107?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140158107","market":"sg","top_or_hot":-1,"title":"Stock Track | Innovent Bio Soars 5.06% Intraday on Strong Q1 Revenue Growth Exceeding 50%","media":"Stock Track","content":"<p>Innovent Biologics' stock soared 5.06% during intraday trading on Thursday, following the release of its first-quarter 2026 financial results.</p><p>The company reported total product revenue exceeding RMB3.8 billion for Q1 2026, representing year-over-year growth of over 50%. This robust performance demonstrates the successful execution of the company's \"dual-engine\" growth strategy, combining domestic business expansion with accelerating global innovation pipeline development.</p><p>Revenue growth was driven by rapid sales expansion of five tyrosine kinase inhibitors following their recent inclusion in China's National Reimbursement Drug List, along with strong performance from core products including Xelmei® (Mazdutide Injection), Xinbile® (Tolecimab Injection), and Xinbimin® (Tituyou Monoclonal Antibody N01 Injection). The company is also advancing three high-value potential molecules—IBI363, IBI343, and IBI324—into or toward global multi-center Phase III clinical studies, bolstering its long-term growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Innovent Bio Soars 5.06% Intraday on Strong Q1 Revenue Growth Exceeding 50%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Innovent Bio Soars 5.06% Intraday on Strong Q1 Revenue Growth Exceeding 50%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-30 10:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Innovent Biologics' stock soared 5.06% during intraday trading on Thursday, following the release of its first-quarter 2026 financial results.</p><p>The company reported total product revenue exceeding RMB3.8 billion for Q1 2026, representing year-over-year growth of over 50%. This robust performance demonstrates the successful execution of the company's \"dual-engine\" growth strategy, combining domestic business expansion with accelerating global innovation pipeline development.</p><p>Revenue growth was driven by rapid sales expansion of five tyrosine kinase inhibitors following their recent inclusion in China's National Reimbursement Drug List, along with strong performance from core products including Xelmei® (Mazdutide Injection), Xinbile® (Tolecimab Injection), and Xinbimin® (Tituyou Monoclonal Antibody N01 Injection). The company is also advancing three high-value potential molecules—IBI363, IBI343, and IBI324—into or toward global multi-center Phase III clinical studies, bolstering its long-term growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1140158107","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140158107","pubTimestamp":1777516512,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Innovent Biologics' stock soared 5.06% during intraday trading on Thursday, following the release of its first-quarter 2026 financial results.The company reported total product revenue exceeding...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"个股赛道|信达生物盘中大涨5.06%Q1营收强劲增长超50%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"Innovent Biologics' stock soared 5.06% during intraday trading on Thursday, following the release of its first-quarter 2026 financial results.The company reported total product revenue exceeding RMB3.8 billion for Q1 2026, representing year-over-year growth of over 50%. This robust performance demonstrates the successful execution of the company's \"dual-engine\" growth strategy, combining domestic business expansion with accelerating global innovation pipeline development.Revenue growth was driven by rapid sales expansion of five tyrosine kinase inhibitors following their recent inclusion in China's National Reimbursement Drug List, along with strong performance from core products including Xelmei® (Mazdutide Injection), Xinbile® (Tolecimab Injection), and Xinbimin® (Tituyou Monoclonal Antibody N01 Injection). The company is also advancing three high-value potential molecules—IBI363, IBI343, and IBI324—into or toward global multi-center Phase III clinical studies, bolstering its long-term growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140158107","isCrawlerRequest":true}